Results showed treatment with D-VRd reduced the risk of disease progression or death by 60% compared with VRd alone. The Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback